By in

Investee business Rapid Dose Therapeutics lists on the Canadian Securities Exchange

Press Release

18 December 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC

 (“Sativa” or the “Company”)

 Investee business Rapid Dose Therapeutics lists on the Canadian Securities Exchange 

Sativa Investments PLC (NEX: SATI),the UK’s first medicinal cannabis investment vehicle,announces that shares in its investee business, Rapid Dose Therapeutics Inc. (“RDT”), the Toronto-based Pharma-Tech company, are now listed on the Canadian Securities Exchange (“CSE”) under the symbol DOSE.  RDT’s shares were admitted to the CSE yesterday, Monday 17th December 2018. 

Full details of the Company’s investment in RDT are included in its release of 23rd May 2018.  At that time, Sativa subscribed for 400,000 RDT shares at C$ 0.50 per share, at a cost of C$ 0.2 million cash.  The closing price of RDT’s shares on the CSE yesterday was C$ 0.85.

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “RDT’s expeditious move to the highly respected CSE reflects the worldwide interest in the fast-developing medicinal cannabis industry. 

“It’s very pleasing to see Sativa’s second investment presenting an initial paper profit for the Company of CS$ 0.14 million, a rise of 70 per cent, after only seven months. 

“RDT’s technology has very positive implications for both Sativa’s medicinal cannabis business and its CBD-focused 100 per cent subsidiary George Botanicals Limited, and we look forward to continued collaboration with RDT alongside our investment.” 

RDT has its own patent-pending proprietary QuickStrip™ technology, a fast-dissolving strip that is placed on or under the tongue, or inside the cheek, which allows medication to enter directly in to the recipient’s system, mimicking an injection path.  Pharmaceuticals, emulsified oils and over-the-counter medicines are used in RDT’s proprietary RDMx mixture technology, which is sold across North America.

The Directors of the Company accept responsibility for the contents of this announcement.

– Ends –

For further information please contact:

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser
Guy Miller and Lucy Williams
Peterhouse Capital Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Abchurch Communications
Julian Bosdet / Dylan Mark /
Alejandra Campuzano
Abchurch Switchboard
SativaInvestments@abchurch-group.com

Joseph Colliver
Chief Financial Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

+44 (0) 20 7469 4633 / 4634


+44 (0) 20 7469 4630
www.abchurch-group.com

Notes to Editors

Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company,Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.

The Company has a presence in Germany through its joint venture with Germany’s Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in to produce medicinal cannabis and CBD products.

The Company also has an option to lease a glasshouse facility in Wiltshire, with an up to 298,806 sq ft build out potential, togrow cannabis plants to produce medicinal cannabis and CBD products, which by law must contain a maximum 0.2 per cent THC.  The Company’s Chief Executive Officer, Geremy Thomas, has a UK hemp growers licence.

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com

By in

Dr Brown appointed to Advisory Board

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC

 (“Sativa” or “the Company”)

Dr Matthew Brown, Pain Medicine & Anaesthetic Consultant appointed to Sativa’s Advisory Board

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle,has appointed Dr Matthew Brown to its Medicinal Cannabis Advisory Board with immediate effect.

Dr Brown is an award-winning Consultant at The Royal Marsden Hospital specialising in pain medicine and anaesthetics and has recently published research into using cannabinoids for cancer pain treatment. Dr Brown holds an honorary research position at the Institute of Cancer Research having completed doctoral research into cancer-related pain at the institution, becoming the firstanaesthetist to complete a higher degree in the Institute’s history.

He has lectured on and produced research covering the breadth of cancer-related pain including chemotherapy induced neuropathy, persistent post-surgical pain as well as reducing pain associated with cancer usinghigh-intensity focused ultrasound (HIFU).  Dr Brown has won numerous awards throughout his career including the War Memorial Scholarship at King’s College London and the Chairman’s Prize on graduation from The Institute of Cancer Research.

Dr Brown’s training has come from a broad range of medical institutions across the UK.  He graduated from King’s College London with distinction in 2004.  His clinical training in pain medicine was gained at The Royal National Orthopaedic Hospital and the National Hospital for Neurology and Neurosurgery.  Dr Brown’s anaesthetic training was undertaken at the Imperial School of Anaesthesia in London, where he also received a placeon the prestigious National Institute for Health Research’s Academic Clinical Fellowship Programme.

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “The new Home Office guidelines determining the prescription of Medicinal Cannabis encompass the treatment of pain and nausea in cancer patients.  Matthew’s qualifications and research in this area add even further to the input of Sativa’s top-level Medicinal Cannabis Advisory Board.  Patient outcome is the clear driver in the highly sensitive and prevalent area of cancer treatment.”

As at the date of this announcement, Dr Brown has unapproved share options in the Company over 76,923 shares at a strike price of 6.5p [NB this calculation is £5,000 / 6.5 pence.]

The Directors of the Company accept responsibility for the contents of this announcement.

-Ends-

For further information please contact:

Geremy Thomas

Founder & Chief Executive Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

Joseph Colliver

Chief Financial Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

NEX Exchange Corporate Adviser

Guy Miller and Lucy Williams

Peterhouse Capital Limited

+44 (0) 20 7469 0930

gm@peterhousecap.com

 

 

 

Financial PR and IR

Abchurch Communications

Julian Bosdet / Dylan Mark /

Alejandra Campuzano

Abchurch Switchboard

SativaInvestments@abchurch-group.com

+44 (0) 20 7469 4633 / 4634

+44 (0) 20 7469 4630

www.abchurch-group.com

Notes to Editors

Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company,Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.

The Company has a presence in Germany through its joint venture with Germany’s Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in for the production of medicinal cannabis and CBD products.

The Company also has an option to lease a glasshouse facility in Wiltshire, with an up to 298,806 sq ft build out potential, togrow cannabis plants to produce medicinal cannabis and CBD products, which by law must contain a maximum 0.2 per cent THC.  The Company’s Chief Executive Officer, Geremy Thomas, has a UK hemp growers licence.

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.

For more information on Sativa Investments, please visit: www.sativainvestments.com

By in

Share Option Scheme

Press Release                                                                                                                 25 October 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC

 (“Sativa” or “Sativa Investments” or the “Company” or the “Group”)

Share Option scheme

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, announces that the Company has adopted the Sativa Investments PLC Share Plan (the “Scheme”), to recognise the work accomplished by the Sativa team to date, to incentivise it going forward, and to enable the Group to continue to attract high calibre recruits as the business expands. 

The Scheme incorporates a tax-advantaged enterprise management incentive (“EMI”) scheme for the grant of share options to key employees, and also allows for the grant of non-tax-advantaged (“NTA”) share options to certain employees, contractors and third parties.  

Initial grants under the Scheme have been made over a total of 24,072,225 ordinary shares of 0.25p each in the Company (“Ordinary Shares”), representing approximately 4.7 per cent of the Company’s current issued share capital.

Of the Ordinary Shares the subject of the options, 13,555,558 (78 per cent) have been made available by Geremy Thomas, the founder and Chief Executive Officer of Sativa, surrendering personal options, otherwise exercisable at a price of 0.5p per share, which had been granted to him on the Company’s admission to trading on the NEX Exchange Growth Market. 

The following options are being granted under the scheme to Directors and Persons Discharging Managerial Responsibilities (“PDMRs”). 

Joseph Colliver, Chief Financial Officer, has been granted options over 3,350,000 Ordinary Shares at an exercise price of 1.5p per share, with one third vesting on the first anniversary of the date of grant, one third on the second anniversary, and one third on the third anniversary.  Joseph has been granted options over a further 4,444,447 Ordinary Shares at an exercise price of 2.25p per share, exercisable on the third anniversary of the date of grant, if remaining in employment of the Company. 

Angus Kerr, a non-Executive Director, has been granted options over 2,222,222 Ordinary Shares at an exercise price of 2.25p per share, exercisable on the third anniversary of the date of grant, if remaining in position. 

Sir Alasdair Breckenridge, a member of the Company’s Medicinal Cannabis Advisory Board, has been granted options over 500,000 Ordinary Shares at an exercise price of 2.25p per share, exercisable on the fifth anniversary of the date of grant, if remaining in position.  

Four non-PDMR employees have been granted options over a further 6,888,889 Ordinary Shares at an exercise price of 2.25p per share, with one third exercisable on the first anniversary of the date of grant, one third on the second anniversary, and one third on the third anniversary, if remaining in employment of the Company. 

Jonathan Wearing, Chairman of Sativa Investments, said: “The implementation of a share option scheme is an important part of the development of the business and has been considered carefully by the Remuneration Committee.  It is indicative of the likely potential of Sativa that Geremy Thomas, the Chief Executive Officer, has committed a proportion of the share options awarded to him personally at listing.” 

In addition, Geremy Thomas has surrendered options over a further 6,666,667 Ordinary Shares granted to him on the Company’s admission to trading on the NEX Exchange Growth Market, also with an exercise price of 0.5p per share.  These options have now been granted as NTA options to JH Racing A&P LTD to fund sponsorship of the Sativa car in the Ginetta Junior Championship 2019 / 2020 season.  The racing series is broadcast on ITV 4 and reaches a combined audience of 19.4 million viewers and a trackside audience of 385,000.  The car and team are heavily branded Sativa Investments PLC and were sponsored previously in Sativa’s name at Geremy Thomas’ personal expense.  

Following the grant of the options as set out above, options over a total of 154,072,225 Ordinary Shares, representing 30 per cent of the Company’s current issued share capital, will be outstanding.

On 18 July 2018, Geremy Thomas exercised options over 500,000 Ordinary Shares and sold these shares at a price of 5p per share. Details of these transactions were inadvertently not announced at the time.

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends  –

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser
Guy Miller and Lucy Williams
Peterhouse Capital Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Abchurch Communications
Julian Bosdet / Dylan Mark /
Alejandra Campuzano
Abchurch Switchboard
SativaInvestments@abchurch-group.com

Joseph Colliver
Chief Financial Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

+44 (0) 20 7469 4633 / 4634


+44 (0) 20 7469 4630
www.abchurch-group.com

Notes to Editors

Sativa looks for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company, Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.

The Company has a presence in Germany through its joint venture with Germany’s Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in for the production of medicinal cannabis and CBD products.

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency (“MHRA”), which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Geremy Thomas

2

Reason for the notification

a)

Position/status

Director / CEO Sativa Investments PLC

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 Sativa Investments PLC

b)

LEI

213800UBHKVCNXTZEZ74

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.25p each

 

ISIN: GB00BFX17474

b)

Nature of the transaction

Surrender of share options

c)

Price(s) and volume(s)

 

20,222,225 ordinary shares at an exercise price of 0.5p (£0.005)

d)

Aggregated information

– Aggregated volume

– Price

 

e)

Date of the transaction

24th October 2018

f)

Place of the transaction

NEX Exchange Growth Market

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Joseph Colliver

2

Reason for the notification

a)

Position/status

Director / CFO Sativa Investments PLC

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 Sativa Investments PLC

b)

LEI

213800UBHKVCNXTZEZ74

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.25p each

 

ISIN: GB00BFX17474

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

3,350,000 at an exercised at 1.5p (£0.015), equal to £50,250

4,444,447 at an exercise price of 2.25p (£0.0225), equal to £100,000

d)

Aggregated information

– Aggregated volume

– Price

 

e)

Date of the transaction

24th October 2018

f)

Place of the transaction

NEX Exchange Growth Market

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Angus Kerr

2

Reason for the notification

a)

Position/status

Non-Executive Director / Sativa Investments PLC

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 Sativa Investments PLC

b)

LEI

213800UBHKVCNXTZEZ74

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.25p each

 

ISIN: GB00BFX17474

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

 

2,222,222 ordinary shares at an exercise price of 2.25p (£0.0225)

d)

Aggregated information

– Aggregated volume

– Price

 

e)

Date of the transaction

24th October 2018

f)

Place of the transaction

NEX Exchange Growth Market

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Sir Alasdair Breckenridge

2

Reason for the notification

a)

Position/status

Member of the Medical Advisory Board / Sativa Investments PLC

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 Sativa Investments PLC

b)

LEI

213800UBHKVCNXTZEZ74

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.25p each

 

ISIN: GB00BFX17474

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

 

500,000 ordinary shares at an exercise price of 2.25p (£0.0225)

d)

Aggregated information

– Aggregated volume

– Price

 

e)

Date of the transaction

24th October 2018

f)

Place of the transaction

NEX Exchange Growth Market

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Geremy Thomas

2

Reason for the notification

a)

Position/status

Director / CEO Sativa Investments PLC

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 Sativa Investments PLC

b)

LEI

213800UBHKVCNXTZEZ74

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.25p each

 

ISIN: GB00BFX17474

b)

Nature of the transaction

Exercise of share options and sale of shares

c)

Price(s) and volume(s)

 

500,000 ordinary shares acquired at an exercise price of 0.5p per share (£0.005) and  sold at 5p per share (£0.05)

d)

Aggregated information

– Aggregated volume

– Price

 

e)

Date of the transaction

18th July 2018

f)

Place of the transaction

NEX Exchange Growth Market

 

By in

Option agreement on 298,806 sq ft glasshouse signed

Press Release                                                                                                                  24 October 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC

 (“Sativa” or “Sativa Investments” or “the Company” or “the Group”)

Option agreement on 298,806 sq ft glasshouse signed

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has now signed the option agreement to lease a 7.53 acre site for medicinal cannabis production in Wiltshire on which the Company intends to build a glasshouse facility.  Further details are included in the Company’s announcement of Thursday 18 October 2018. 

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends  –

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser
Guy Miller and Lucy Williams
Peterhouse Capital Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Abchurch Communications
Julian Bosdet
Dylan Mark
Alejandra Campuzano
Switchboard
SativaInvestments@abchurch-group.com

Joseph Colliver
Chief Financial Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

+44 (0) 20 7469 4631
+44 (0) 20 7469 4633
+44 (0) 20 7469 4634
+44 (0) 20 7469 4630
www.abchurch-group.com

Notes to Editors

Sativa looks for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company, Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.

The Company has a presence in Germany through its joint venture with Germany’s Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in for the production of medicinal cannabis and CBD products.

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency (“MHRA”), which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com

By in

Change in Board responsibilities

Press Release                                                                                                                 24 October 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC

 (“Sativa” or “Sativa Investments” or “the Company” or “the Group”)

Change in Board responsibilities

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, announces that Mark Blower, currently an Executive Director of the Company, is moving to a non-Executive Director role with immediate effect.

–  Ends  –

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser
Guy Miller and Lucy Williams
Peterhouse Capital Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Abchurch Communications
Julian Bosdet
Dylan Mark
Alejandra Campuzano
Switchboard
SativaInvestments@abchurch-group.com

Joseph Colliver
Chief Financial Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

+44 (0) 20 7469 4631
+44 (0) 20 7469 4633
+44 (0) 20 7469 4634
+44 (0) 20 7469 4630
www.abchurch-group.com

Notes to Editors

Sativa looks for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company, Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.

The Company has a presence in Germany through its joint venture with Germany’s Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in for the production of medicinal cannabis and CBD products.

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency (“MHRA”), which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com